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In view of the importance of the report of the German
Academy of Sciences (Leopoldina 2015), discussion on the
health impact of Omics was invited (Ku¨nzli 2015). We
would like to expand the view previously published in this
journal (Razum et al. 2015).
Modern accounts of what now constitutes public health
have broadened the meaning of the latter, which has come
to mean any form of collective action that aims to improve
the health of populations (Porter 1998). In that sense, cat-
egories, such as medicine, epidemiology and new
technologies (to name a few), are species concepts, sub-
jected to a wider genus proximum, public health. In this
context, the fascinating field of Omics (genomics, tran-
scriptomics, proteomics, metabolomics, microbiomics,
etc.) and Big Data, with its various applications, has
already started to revolutionize the landscape of public
health, since the beginning of the 21st century (Brand et al.
2008). However, individual scholars and academic insti-
tutes have failed to catch sight of the current successes of
Omics and Big Data, recognize their entire societal
potential and envisage the future (Bayer and Galea 2015;
Leopoldina 2015). Moreover, misconceptions of the health
impact of Omics have misled scholars and part of the
public to doubt their effectiveness and adopt opinions that
hinder the implementation of Omics in health systems.
We, on the other hand, argue that Omics are now an
organic part of good governance in public health. The idea
of modern public health without Omics is simply incon-
ceivable! The reasons for this rely on arguments based on
both scientific and societal values.
Going beyond phenotypes, Omics allow for the detec-
tion of Mendelian diseases almost to 100 %. And not only
that! Identification of resilient individuals opens new
highways towards elucidation of genetic disorders and new
treatment approaches (Chen et al. 2016). Newborn
screening programs are a reality, a current success of
Omics, which allows for timely diagnosis even before
clinical presentation and enables improved life- and
healthspan for affected children. Women with BRCA1
mutations, identified through genetic testing and offered
intensive preventive options, are also a reality. Yes, it has
not been easy for multifactorial or complex diseases, but
with the continued thrust, it will be achievable in the
foreseeable future. There are already about 1000 genetic
tests for multifactorial disorders and hundreds more are
currently being tested, with new approaches, such as the
diseasome, facilitating the conceptualization of the gen-
ome-disease interactions. For the patients with potentially
life threatening multifactorial disorders, such as cardiac
channelopathies and cardiomyopathies, timely diagnosis
and treatment options, are already becoming a reality.
Apart from diagnosis, Omics have also been changing
the way we approach treatment. An ever growing list of
genetic polymorphisms is now used as a basis for
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predicting response to more than 100 drugs. Pharmacoge-
nomics allow for the identification of patients most likely
to respond to a certain treatment, enable tailoring of drug
dosage and minimize adverse drug reactions. The impor-
tance of pharmacogenomics becomes even more evident if
we take into account that 38–75 % of patients are estimated
to be unresponsive to drugs (Lehrach 2015).
A third pillar of Omics applications is related to their
ability to fully exploit the potential of traditional public
health interventions. Although a relatively new approach,
genetic profiling enables population stratification as to their
genetic predisposition and guides prevention programs
accordingly, thus rendering them more effective in terms of
cost and benefit. In an uncertain global economic land-
scape, cost effectiveness of any public health intervention
is of major importance and Omics can help us both opti-
mize the outcome and reduce the costs of our interventions.
Effective screening and prevention programs, early
diagnosis, proper treatment and minimization of costs
enabled by Omics are obvious benefits for both patients
and health care systems. Is that not, after all, the essence of
successful public health programs?
The contribution of Omics to public health transcends
conventional academic and industrial barriers and trans-
forms public health in ways that traditional approaches
simply cannot. Apart from public health interventions, we
also need effective drugs in our armamentarium. In an era
when the rate of new drug approvals stagnates, drug
development has moved from the classical clinical devel-
opment approach of the many, sequential, distinct phases,
to a more integrative approach with adaptive clinical trial
designs. This is a pure effect of the implementation of
Omics approaches and has already started delivering its
first results (Schulthess et al. 2015).
Furthermore, and perhaps even more excitingly,
knowledge in the form of integrated and socially mean-
ingful Omic data has increasingly been conceptualized as
public good. Sharing of Omic data from clinical trials
enhances public confidence in clinical trials results and
fosters the innovation capability of the biopharmaceutical
industry, thus leading to the production of targeted drugs
that allow for the realization of personalized medicine.
However, the social and economic externalities of Omics
do not stop here. Health Data Cooperatives enabled by
Omics, such as MIDATA.coop, empower citizens to the
benefit of individuals, healthcare systems and the society
(Hafen et al. 2014).
From the above, it is obvious that we are in the middle
of a major paradigm shift that leads us towards a ‘systems
thinking’ as to disease etiology, prevention and treatment
(Brand 2011). However, we are confronted with challenges
that need to be addressed. It is clear that we will have to go
through a period of ‘normal science’ (in the Kuhnian sense)
(Kuhn 1962) which will shed light on the constant inter-
actions between the genome and the phenome (Houle et al.
2010). Moreover, the impact of Omics on public health
cannot be fully realized, unless their implementation and
integration in health care systems are fully deployed. A
critical mass has to be reached…
Effective implementation of Omics-based technologies
requires coordinated actions and appropriate modifications
of public health and health governance systems at all levels
(Brand et al. 2012). Starting in Germany and followed by
other European Member States, significant work towards
this direction has been done by the Public Health Genomics
European Network (PHGEN) (http://www.phgen.eu) and
guidelines have been developed to ensure the maximum
impact on health and economic growth in the health sector.
It is incontrovertible that the traditional approaches
based on epidemiology, such as tobacco control, have
conferred significant advantages in the health of popula-
tions. However, they seem to have reached their capacity as
to the added value they can confer, at least to parts of the
population which have already benefited from such inter-
ventions (e.g., people who have quitted smoking). On the
other hand, Omics have been providing sound evidence of
their potential, as an essential part of good governance, to
radically transform the landscape in public health. Unless
the skepticism of traditional public health programs
towards Omics can present us a sustainable alternative to
Omics, there is no other way, beneficial to the population,
for them, but to welcome new partners and new approaches
to common scopes. The high relevance of the field of
Omics for public health and health policy has recently also
been expressed by European policymakers. In the Council
conclusions on personalized medicine for patients, which
has been developed under the Luxembourg Presidency in
2015 (Council 2015), the step-by-step implementation of
Public Health Genomics, both at European Union and
national level, is encouraged. Public Health Genomics
offers a debate platform, where a productive ‘innovation
diplomacy’ can find place—we welcome constructive
contributions!
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